The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
14-Jul-21
Undisclosed
Target:
New Day Aluminum LLC
Acquiror:
Concord Resources Ltd.
Advised DADA Holdings on the sale of its majority stake in New Day Aluminum LLC to Concord Resources Ltd.
01-Jun-21
Undisclosed
Target:
VEP Healthcare
Acquiror:
U.S. Acute Care Solutions
Advised VEP Healthcare, a leading, physician-owned provider of clinical management services in emergent and inpatient settings in the United States, on its merger with U.S. Acute Care Solutions
07-May-21
N/A
Target:
MindPath Care Centers
Acquiror:
Community Psychiatry
Advised Community Psychiatry, a leading provider of outpatient behavioral health services with a focus on high-quality clinically-driven care, on its acquisition of MindPath Care Centers, deepening its national presence to more than 350 providers across the US
26-Feb-21
$2.0 billion
Target:
MDLIVE
Acquiror:
Cigna
Advising Cigna on the acquisition of MDLIVE, a virtual care delivery platform, by Evernorth, Cigna’s health services portfolio
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
11-Feb-21
Undisclosed
Target:
Alumisource Corporation
Acquiror:
Sims Limited
Advised Sims Limited, a global leader in metal recycling and electronics recovery, on the acquisition of certain commercial and operating assets of Alumisource Corporation
09-Feb-21
Undisclosed
Target:
US Acute Care Solutions
Acquiror:
Apollo Hybrid Value Fund
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
29-Dec-20
$110 million
Target:
Biogix, Inc.
Acquiror:
Alliance Pharma plc
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
01-Oct-20
$1.05 billion
Target:
Akorn, Inc.
Acquiror:
First Lien Term Loan Lenders
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
15-Sep-20
$NA
Target:
Surgery Partners’ Anesthesia Services
Acquiror:
NorthStar Anesthesia
Advised Surgery Partners, a leading owner and operator of surgical facilities, on the divestiture of its anesthesia services business to NorthStar Anesthesia
12-Aug-20
$225 million
Target:
340B Link
Acquiror:
Omnicell
Advising Omnicell, a leading provider of medication management solutions and adherence tools for health systems and pharmacies, on the acquisition of the 340B Link business from Pharmaceutical Strategies Group (PSG)
01-Jul-20
$225 million
Target:
Cello Health plc
Acquiror:
Arsenal Capital Partners
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
10-Jun-20
$3.9 billion
Target:
Global collaboration agreement with Genmab A/S
Acquiror:
AbbVie, Inc
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
03-Jun-20
$NA
Target:
Cerner RevWorks
Acquiror:
R1 RCM
Advised Cerner Corporation, a leader in healthcare information technology, on its sale of its RevWorks revenue cycle management services business to R1 RCM, a leading provider of technology-enabled RCM services
23-Mar-20
$68 million
Target:
Abacus Health Products, Inc.
Acquiror:
Charlotte’s Web Holdings, Inc.
Advised Abacus Health Products, Inc., a leader in over-the-counter (“OTC”) topical products combining active pharmaceutical ingredients with cannabidiol (“CBD”) hemp extract, on its sale to the Charlotte’s Web Holdings, Inc., a market leader in hemp-derived CBD wellness products.
18-Mar-20
$NA
Target:
Centrifuge and processing equipment business of Koki Holdings Co., Ltd.
Acquiror:
Eppendorf AG
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
15-Jan-20
$NA
Target:
OurHealth
Acquiror:
General Atlantic
Advised OurHealth, a provider of onsite and near-site employer-sponsored primary care clinics, on its sale to General Atlantic and merger with Marathon Health
14-Jan-20
$537 million
Target:
Hycroft Mining Corporation
Acquiror:
Mudrick Capital Acquisition Corporation
Advised Hycroft Mining Corporation, a US-based, gold and silver producer operating the Hycroft mine located in Northern Nevada, on the sale of substantially all of its assets to Mudrick Capital Acquisition Corporation
19-Dec-18
$NA
Target:
Pfizer Inc. Consumer Health Business
Acquiror:
GlaxoSmithKline plc
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
19-Dec-18
$NA
Target:
Starpharma Holdings Limited, patented VivaGel BV® product
Acquiror:
ITF Pharma, US subsidiary of Italfarmaco S.p.A.
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
30-Nov-18
$NA
Target:
Aisthesis
Acquiror:
NAPA Management Services Corporation
Advised Aisthesis, a portfolio company of Triton Pacific Capital Partners, on its sale to NAPA, a portfolio company of American Securities
01-Nov-18
$NA
Target:
Long-term lithium hydroxide offtake agreement with Mitsui & Co.
Acquiror:
Kidman Resources Limited
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a lithium hydroxide offtake agreement with Mitsui & Co., a leading global marketing and trading conglomerate based in Japan. The agreement is for an initial term of two years, plus two 2-year term extension options
15-Aug-18
$3.9 billion
Target:
Common shares and common share purchase warrants in Canopy Growth
Acquiror:
Constellation Brands
Advised Canopy Growth on a C$5bn investment by Constellation Brands. As consideration for the investment, Constellation received newly issued Canopy common shares and common share purchase warrants
17-May-18
$NA
Target:
Long-term lithium hydroxide offtake agreement with Tesla, Inc.
Acquiror:
Kidman Resources Limited
Advised Kidman Resources Limited, an ASX-listed hard rock lithium mining company with a 50% interest in the West Australian Mt. Holland lithium project, on a lithium hydroxide offtake agreement with Tesla, Inc., a global leader in electric vehicle, energy storage and solar panel design, development and manufacturing. The agreement is for an initial term of three years on a fixed-price take-or-pay basis and contains two 3-year term renewal options
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt